[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2007009700A3 - Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome - Google Patents

Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome Download PDF

Info

Publication number
WO2007009700A3
WO2007009700A3 PCT/EP2006/006974 EP2006006974W WO2007009700A3 WO 2007009700 A3 WO2007009700 A3 WO 2007009700A3 EP 2006006974 W EP2006006974 W EP 2006006974W WO 2007009700 A3 WO2007009700 A3 WO 2007009700A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
metabolic syndrome
pyrazoline compounds
lipid parameters
substituted pyrazoline
Prior art date
Application number
PCT/EP2006/006974
Other languages
French (fr)
Other versions
WO2007009700A2 (en
Inventor
Helmut H Buscmann
Original Assignee
Esteve Labor Dr
Helmut H Buscmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05384013A external-priority patent/EP1749527A1/en
Application filed by Esteve Labor Dr, Helmut H Buscmann filed Critical Esteve Labor Dr
Publication of WO2007009700A2 publication Critical patent/WO2007009700A2/en
Publication of WO2007009700A3 publication Critical patent/WO2007009700A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome in humans and animals.
PCT/EP2006/006974 2005-07-15 2006-07-15 Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome WO2007009700A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05384013A EP1749527A1 (en) 2005-07-15 2005-07-15 Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome
EP05384013 2005-07-15
US70547905P 2005-08-05 2005-08-05
US60/705,479 2005-08-05

Publications (2)

Publication Number Publication Date
WO2007009700A2 WO2007009700A2 (en) 2007-01-25
WO2007009700A3 true WO2007009700A3 (en) 2007-04-05

Family

ID=37450851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/006974 WO2007009700A2 (en) 2005-07-15 2006-07-15 Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome

Country Status (2)

Country Link
ES (1) ES2326857B1 (en)
WO (1) WO2007009700A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1384477A1 (en) * 2001-04-06 2004-01-28 Laboratorios Del Dr. Esteve, S.A. Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
WO2005077909A1 (en) * 2004-02-17 2005-08-25 Laboratorios Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861303A1 (en) * 2003-10-24 2005-04-29 Sanofi Synthelabo Use of pyrazole derivative as cannabinoid CB1 receptor antagonist, for treatment and prevention of metabolic syndrome, particularly cardiovascular risks, dyslipidemia and liver disease associated with obesity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1384477A1 (en) * 2001-04-06 2004-01-28 Laboratorios Del Dr. Esteve, S.A. Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
WO2005077909A1 (en) * 2004-02-17 2005-08-25 Laboratorios Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Der Begriff "Metabolisches Syndrom" ist unklar", DEUTSCHE APOTHEKER ZEITUNG, vol. 42, 20 October 2005 (2005-10-20), pages 8, XP002360775 *
ECKEL R H ET AL: "The metabolic syndrome", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 365, no. 9468, 16 April 2005 (2005-04-16), pages 1415 - 1428, XP004849990, ISSN: 0140-6736 *
SIDDALL R: "RIO-DIABETES: RIMONABANT SHOWS PROMISE IN TYPE 2 DIABETES", BRITISH JOURNAL OF CARDIOLOGY, LONDON, GB, vol. 12, no. 4, July 2005 (2005-07-01), pages 257, XP009053958, ISSN: 0969-6113 *

Also Published As

Publication number Publication date
ES2326857B1 (en) 2010-05-11
ES2326857A1 (en) 2009-10-20
WO2007009700A2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
WO2007009701A3 (en) Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
PL2346864T3 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases.
IL191772A0 (en) Compounds for the treatment of inflammatory disorders and microbial diseases
IL191637A0 (en) Compounds for the treatment of inflammatory disorders and microbial diseases
WO2007115821A3 (en) Organic compounds
ZA200803440B (en) Compounds for the treatment of metabolic disorders
IL186616A0 (en) Spiro-oxindole compounds and their uses as therapeutic agents
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
WO2006131591A3 (en) An entacapone-containing oral dosage form
IL186615A0 (en) Spiroheterocylic compounds and their uses as therapeutic agents
BRPI0922233A2 (en) compounds, pharmaceutical compositions and methods for use in the treatment of metabolic syndromes.
ZA200800448B (en) Methods and compositions for the prevention and treatment of inflammatory disease
WO2010077339A3 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
SI2120923T1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
BRPI0912412A2 (en) fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases.
WO2007009686A3 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
NL1034216A1 (en) Improved structure of Inline Skates.
ITRM20050179A1 (en) APPLICABLE COMPOSITION FOR THE TREATMENT OF PARADONTAL DISEASES.
EP1865952A4 (en) Histamine-containing composition for the treatment of allergic diseases
WO2009074498A8 (en) Medical use of 3- (2, 2, 2-trimethylhydrazinixm) propionate orotate
WO2007009700A3 (en) Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome
GB0604782D0 (en) Use of substituted pyrimidinyl-2-piperazine compounds for the treatment of food related disorders
WO2007009704A3 (en) Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
WO2007009707A3 (en) Use of substituted pyrazoline compounds for the treatment of coagulation related diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 200850004

Country of ref document: ES

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P200850004

Country of ref document: ES

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06762616

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 200850004

Country of ref document: ES

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: 200850004

Country of ref document: ES

Kind code of ref document: A